Skip to content

Phase 1/2 study of treatment for spinal cord injury with autologous mononuclear cells derived from bone marrow

Phase 1/2 study of treatment for spinal cord injury with autologous mononuclear cells derived from bone marrow - Phase 1/2 study of treatment for spinal cord injury with autologous mononuclear cells derived from bone marrow

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000007599
Enrollment
10
Registered
2012-03-29
Start date
2012-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal cord injury

Interventions

Sponsors

Department of plastic surgery, Kitano hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patient whose ASIA classification is A, B or C (at the time of registration) 2. Patient who can participate in the study between 3 weeks and 1 year after injury (at the time of registration) 3. Patient who has partial damage in the spinal cord diagnosed by MR imaging 4. Patient who has provided written informed consent to participate in the study

Exclusion criteria

Exclusion criteria: 1. Patient whose spinal cord is transected completely 2. Patient with central spinal cord injury 3. Patient whose SOFA score is more than 3 (at the time of registration) 4. Patient with hepatitis B, hepatitis C, HIV, ATL,or papovavirus B19 5. Patient with malignant tumor within 5 years before registration 6. Patient with myeloproliferative disease Patient with myelodysplastic syndrome Patient with ischemic heart disease, difficult to control Patient with autoimmune disease Patient with spinal canal stenosis Patient with motor paralysis in the extremities due to the dysfunction of central nervous system before spinal cord injury Patient with hepatic dysfunction Patient with renal failure Patient with psychological diseases, difficult to control 7. Patient with history of participation of other clinical researches within 6 months before registration Patient who is a participant in other studies 8. Patient who is pregnancy or suspicion of pregnancy 9. Patient who is judged to be inappropriate as a participant in this study by researchers

Design outcomes

Primary

MeasureTime frame
Type and grade of adverse events Frequency of adverse events

Secondary

MeasureTime frame
To investigate the recovery of motor and sensory function after transplantaion of bone marrow-derived mononuclear cells into cerebrospinal fluid of patients with subacute spinal injury

Countries

Japan

Contacts

Public ContactYoshihisa Suzuki

The Tazuke Kofukai Medical Research Institute, Kitano Hospital Plastic surgery, 5th laboratory

yo-suzuki@kitano-hp.or.jp06-6312-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026